Sermorelin

Background

Sermorelin is the first 29 amino acids of human growth hormone–releasing hormone (GHRH 1–29 NH2), which corresponds to the active fragment of the full 44-amino-acid hormone. It was approved in 1997 (as Geref) for diagnosis and treatment of pediatric GH deficiency. The branded pediatric product was discontinued in 2008, but the molecule remains in use through compounding pharmacies and research suppliers.

The clinical reasoning behind GHRH analogs vs. recombinant GH is that stimulating the pituitary preserves negative feedback, pulsatility, and downstream regulation — the body still controls the release. This produces a smaller, more physiologic GH/IGF-1 signal with a cleaner side-effect profile.

Mechanism in depth

Sermorelin binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering cAMP-mediated GH synthesis and release. Key features:

1. Pulsatile release — GH is released as a bolus, consistent with natural physiology, rather than the elevated steady-state seen with rhGH.
2. Preserved feedback — somatostatin and IGF-1 negative feedback continue to operate, capping the maximum signal.
3. Synergy with GHRPs — GH secretagogues like ipamorelin act via the ghrelin/GHS-R pathway, complementary to GHRH. Combined stimulation produces a larger GH pulse than either alone.

The short half-life (under 30 minutes) means timing matters. Bedtime dosing aligns with the natural overnight GH pulse, amplifying it rather than replacing it.

Human evidence

Sermorelin has the most adult human data of any GHRH analog used in body-composition contexts:

• Pediatric GHD trials (1990s) — established efficacy and safety in children with short stature due to GH deficiency.
• Adult older-adult studies (Walker, Khorram, Vittone) — daily injection raises IGF-1 modestly, improves some body composition metrics over 3–6 months, with manageable side effects.
• Mixed sleep and quality-of-life endpoints — sleep architecture data is generally favorable; subjective well-being endpoints are positive but soft.

There is no adequately powered modern adult RCT for the off-label "anti-aging" use. Most current adult use is extrapolated from pediatric data and the older adult studies above.

Animal evidence

Extensive but less central to current discussion, since human data exists. Rodent and primate models established the dose-response and the pulsatility advantage that motivated clinical development.

Stack synergy

Standard pairings:

• Ipamorelin — selective GH secretagogue (ghrelin pathway). The sermorelin + ipamorelin stack is one of the most common GH-axis protocols. Additive GH release without significant cortisol or prolactin elevation.
• CJC-1295 — longer-acting GHRH analog. Generally either-or rather than both, since they compete for the same receptor.
• MK-677 (oral) — GH secretagogue; sometimes substituted for injectable ipamorelin.

Avoid combining with high-dose rhGH (redundant and additive risk) or with strong somatostatin agonists (which blunt the effect).

Open questions

• Optimal cycling pattern for chronic adult use — daily indefinite vs. 5/2 vs. blocks?
• Does sermorelin reliably outperform placebo on functional endpoints (strength, VO2max, body fat) in adults without diagnosed GHD?
• Long-term cancer risk from chronic mild IGF-1 elevation in healthy older adults remains epidemiologically uncertain.
• Why does sermorelin outperform CJC-1295 on some endpoints in some users, and the reverse in others? Pulsatility vs. AUC tradeoffs are not well-mapped.